Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesetaxel - Odonate Therapeutics

Drug Profile

Tesetaxel - Odonate Therapeutics

Alternative Names: DJ-927

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Genta (CEASED); Odonate Therapeutics
  • Class Amines; Antineoplastics; Benzoates; Carbamates; Dioxolanes; Pyrimidines; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Preclinical Brain metastases
  • Discontinued Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 21 Oct 2019 Odonate Therapeutics completes enrolment in the phase III CONTESSA trial for Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Russia, Singapore, South Korea, Spain, Taiwan, Thailand, Ukraine, United Kingdom and USA (NCT03326674)
  • 03 Apr 2019 Preclinical trials in Brain metastases in USA (PO) before April 2019
  • 03 Apr 2019 Preclinical pharmacokinetics data from a Brain metastases released by Odonate Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top